934666-06-5

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 2-(3-hydroxy-3-azetidinyl)-, 1,1-diMethylethyl ester
• Synonyms: 1-Piperidinecarboxylic acid, 2-(3-hydroxy-3-azetidinyl)-, 1,1-diMethylethyl ester;2-(3-Hydroxyazetidin-3-yl)piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 934666-06-5
• Molecular Formula: C13H24N2O3
• Molecular Weight: 256.34126
• Mol File: 934666-06-5.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 2-(3-hydroxy-3-azetidinyl)-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 2-(3-hydroxy-3-azetidinyl)-, 1,1-diMethylethyl ester(934666-06-5)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 2-(3-hydroxy-3-azetidinyl)-, 1,1-diMethylethyl ester(934666-06-5)

Safety Data

• Hazardous Substances Data: 934666-06-5(Hazardous Substances Data)

Usage

General Description

1-Piperidinecarboxylic acid, 2-(3-hydroxy-3-azetidinyl)-, 1,1-diMethylethyl ester is a chemical compound that belongs to the class of piperidinecarboxylic acid derivatives. It is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various drugs. 1-Piperidinecarboxylic acid, 2-(3-hydroxy-3-azetidinyl)-, 1,1-diMethylethyl ester has been studied for its potential applications in the treatment of neurological disorders and as an anti-inflammatory agent. It is known for its high stability and low toxicity, making it a desirable compound for use in drug development. Additionally, it has also been investigated for its potential use as a building block in organic synthesis due to its reactivity and versatility.

Upstream product

• 934664-27-4 1,1-dimethylethyl 2-(3-hydroxy-1-{[(phenylmethyl)oxy]carbonyl}azetidin-3-yl)piperidine-1-carboxylate 
• 934665-53-9 1,1-dimethylethyl (2S)-2-(1-{[(phenylmethyl)oxy]carbonyl}-3-{[(2R)-3,3,3-trifluoro-2-(methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-yl)piperidine-1-carboxylate 
• 934665-52-8 1,1-dimethylethyl (2R)-2-(1-{[(phenylmethyl)oxy]carbonyl}-3-{[(2R)-3,3,3-trifluoro-2-(methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-yl)piperidine-1-carboxylate 
• 388077-74-5 rac-N-(tert-butoxycarbonyl)piperidine-2-carboxamide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 4043-87-2 pipecolic Acid 
• 98303-20-9 1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid 
• 153749-89-4 2-cyanopiperidine-1-carboxylic acid tert-butyl ester 
• 109-04-6 2-bromo-pyridine 
• 1415560-00-7 C₁₀H₉F₃N₂O₂*ClH 
• 934665-54-0 1,1-dimethylethyl (2R)-2-(3-hydroxy-1-{[(phenylmethyl)oxy]carbonyl}azetidin-3-yl)piperidine-1-carboxylate 
• 26250-84-0 (S)-(-)-1-(tert-butoxycarbonyl)-2-piperidinecarboxylic acid 
• 28697-17-8 N-BOC-D-pipecolic acid 

Relevant articles and documents

PROCESS FOR THE PRODUCTION OF COBIMETINIB

The present invention relates to a novel route of synthesis for the production of enantiomerically pure Cobimetinib, new intermediates in the synthesis of Cobimetinib and an amorphous Cobimetinib hemifumarate salt comprising a high salt content.

Synthesis method of cobimetinib

The invention discloses a synthesis method of cobimetinib. The method comprises the following steps: respectively carrying out salt forming reaction and bromination reaction on (R)-N-Boc-2-piperidinecarboxylic acid, silver nitrate (or mercuric oxide) and

Preparation method of cobimetinib

The invention discloses a preparation method of cobimetinib (Cobimetinib, XL518, GDC-0973) (I). The method includes the preparation steps of preparing an intermediate [2-oxo-2-((2S)-1-t-butyloxycarboryl-2-based]acetate through acyl cyanide formation, hydrolysis, esterification and Boc prortection with (2S)-2-pipecolic acid as the raw material, preparing an intermediate (2S)-1-t-butyloxycarboryl-2-(3-azetidinol-3-based)piperidine by conducting the addition reaction, the reduction action and the cyclization reaction on the intermediate body, and making the intermediate (2S)-1-t-butyloxycarboryl-2-(3-azetidinol-3-based)piperidine and a side chain subjected to a condensation reaction to obtain the cobimetinib (I). According to the preparation method, raw materials can be easily obtained, the process is simple, and the method is economical, environmentally friendly and suitable for industrialized production.